About La Jolla Pharmaceutical
La Jolla Pharmaceutical is a company based in San Diego (United States) founded in 1989 was acquired by Innoviva in July 2022. The company has 71 employees as of December 31, 2022. La Jolla Pharmaceutical has completed 1 acquisition, including Tetraphase Pharmaceuticals. La Jolla Pharmaceutical offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. La Jolla Pharmaceutical operates in a competitive market with competitors including Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
- Headquarter San Diego, United States
- Employees 71 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Innoviva, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of La Jolla Pharmaceutical
La Jolla Pharmaceutical offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Treatment for critical care conditions in patients.
Therapy for infectious diseases caused by bacteria.
Treatment for drug-resistant microorganisms.
Investigational therapy for gonorrhea infections.
People of La Jolla Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of La Jolla Pharmaceutical
Investors in La Jolla Pharmaceutical
La Jolla Pharmaceutical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Innoviva and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
Respiratory prescription drugs are developed and in-licensed for COPD treatment.
|
Locked | Locked | Locked |
Investor details for La Jolla Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by La Jolla Pharmaceutical
La Jolla Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tetraphase Pharmaceuticals.
Investment portfolio details for La Jolla Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tetracycline analogs are developed for multidrug-resistant bacterial infections.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for La Jolla Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - La Jolla Pharmaceutical
Detailed financials for La Jolla Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
La Jolla Pharmaceutical Comparisons
Peer comparison for La Jolla Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of La Jolla Pharmaceutical
La Jolla Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of hematologic diseases
|
|
| Locked | Locked | Locked |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating multiple diseases
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using targeted gene editing platforms.
|
Detailed competitors of La Jolla Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on La Jolla Pharmaceutical
Complete news archive for La Jolla Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about La Jolla Pharmaceutical
La Jolla Pharmaceutical was founded in 1989 and raised its 1st funding round 22 years after it was founded.
La Jolla Pharmaceutical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Larry Edwards is the current CEO of La Jolla Pharmaceutical.
As of Dec 31, 2022, the latest employee count at La Jolla Pharmaceutical is 71.
Annual revenue of La Jolla Pharmaceutical is $75.72M as on Dec 31, 2021.
La Jolla Pharmaceutical is developing therapies for treating life-threatening diseases. The companys lead product candidate, LJPC-401 is its a formulation of synthetic human hepcidin (peptide hormones) for the potential treatment of hemochromatosis, and beta thalassemia. Its in phase II clinical trials. Other candidates of the company include LJPC-30Sa and LJPC-30Sb, are next-generation gentamicin derivatives for the treatment of bacterial infections and rare genetic disorders, LJPC-501 is its proprietary formulation of angiotensin II for treating catecholamine-resistant hypotension and hepatorenal syndrome.
La Jolla Pharmaceutical's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
La Jolla Pharmaceutical offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
La Jolla Pharmaceutical has made 1 acquisition, including Tetraphase Pharmaceuticals.
La Jolla Pharmaceutical has 2 investors. Key investors include Innoviva, and HealthCare Royalty Partners.